PMID- 35015699
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220224
IS  - 2049-3614 (Print)
IS  - 2049-3614 (Electronic)
IS  - 2049-3614 (Linking)
VI  - 11
IP  - 2
DP  - 2022 Feb 4
TI  - Immune checkpoint inhibitors, endocrine adverse events, and outcomes of melanoma.
LID - e210562 [pii]
LID - 10.1530/EC-21-0562 [doi]
AB  - OBJECTIVE: Immune checkpoint inhibitors (ICI) can cause endocrine adverse events. 
      However, endocrine adverse events (AEs). However, endocrine AEs could be related 
      to better treatment outcomes. Our aim was to investigate whether this holds true 
      in a real-world setting of metastatic melanoma patients. DESIGN: A retrospective 
      single-institution study. METHODS: We included 140 consecutive metastatic 
      melanoma patients treated with ICI between January 2012 and May 2019. We assessed 
      the endocrine toxicity and the best possible treatment outcomes from electronic 
      patient records, including laboratory parameters and radiological images. 
      RESULTS: Of the treated patients, 21 patients (15%) were treated with ipilimumab, 
      46 (33%) with nivolumab, 67 (48%) with pembrolizumab, and 6 (4%) with combination 
      therapy (ipilimumab + nivolumab). Endocrine AEs appeared in 29% (41/140) 
      patients. Three patients had two different endocrine AEs. Thyroid disorders were 
      the most common: 26% (36/140), followed by hypophysitis: 4% (5/140). Three 
      subjects (2%, 3/140) were diagnosed with autoimmune diabetes. Three patients had 
      to terminate treatment due to endocrine toxicity. Radiological manifestations of 
      endocrine AEs were found in 16 patients (39%, 16/41). Endocrine toxicity was 
      associated with significantly better treatment outcomes. Median progression-free 
      survival (8.1 months, range 5.1-11.1 months vs 2.7 months, range 2.4-3.0 months, 
      P < 0.001), and median overall survival (47.5 months, range 15.5-79.5 months vs 
      23.7 months, range 15.3-32.1 months, P = 0.035) were longer for patients 
      experiencing endocrine AEs. CONCLUSIONS: The higher number of endocrine AEs 
      suggest that regular laboratory monitoring aids in AE detection. Endocrine AEs in 
      metastatic melanoma may correlate with better treatment outcomes.
FAU - Karhapaa, Hanna
AU  - Karhapaa H
AUID- ORCID: 0000-0002-6009-5027
AD  - Medical Faculty, University of Helsinki, Helsinki, Finland.
AD  - Department of Oncology, Comprehensive Cancer Centre, Helsinki University 
      Hospital, Helsinki, Finland.
FAU - Makela, Siru
AU  - Makela S
AD  - Medical Faculty, University of Helsinki, Helsinki, Finland.
AD  - Department of Oncology, Comprehensive Cancer Centre, Helsinki University 
      Hospital, Helsinki, Finland.
FAU - Lauren, Hanna
AU  - Lauren H
AD  - Medical Faculty, University of Helsinki, Helsinki, Finland.
AD  - Department of Radiology, HUS Medical Imaging Centre, University of Helsinki and 
      Helsinki University Hospital, Helsinki, Finland.
FAU - Jaakkola, Marjut
AU  - Jaakkola M
AD  - Medical Faculty, University of Helsinki, Helsinki, Finland.
AD  - Department of Radiology, HUS Medical Imaging Centre, University of Helsinki and 
      Helsinki University Hospital, Helsinki, Finland.
FAU - Schalin-Jantti, Camilla
AU  - Schalin-Jantti C
AD  - Medical Faculty, University of Helsinki, Helsinki, Finland.
AD  - Endocrinology, Abdominal Centre, University of Helsinki and HUS, Helsinki, 
      Finland.
FAU - Hernberg, Micaela
AU  - Hernberg M
AD  - Medical Faculty, University of Helsinki, Helsinki, Finland.
AD  - Department of Oncology, Comprehensive Cancer Centre, Helsinki University 
      Hospital, Helsinki, Finland.
LA  - eng
PT  - Journal Article
DEP - 20220204
PL  - England
TA  - Endocr Connect
JT  - Endocrine connections
JID - 101598413
PMC - PMC8859941
OTO - NOTNLM
OT  - CTLA-4
OT  - PD-1
OT  - endocrine adverse event
OT  - immune checkpoint inhibitor
OT  - toxicity
EDAT- 2022/01/12 06:00
MHDA- 2022/01/12 06:01
PMCR- 2022/01/11
CRDT- 2022/01/11 17:34
PHST- 2021/12/23 00:00 [received]
PHST- 2022/01/11 00:00 [accepted]
PHST- 2022/01/12 06:00 [pubmed]
PHST- 2022/01/12 06:01 [medline]
PHST- 2022/01/11 17:34 [entrez]
PHST- 2022/01/11 00:00 [pmc-release]
AID - e210562 [pii]
AID - EC-21-0562 [pii]
AID - 10.1530/EC-21-0562 [doi]
PST - epublish
SO  - Endocr Connect. 2022 Feb 4;11(2):e210562. doi: 10.1530/EC-21-0562.